


Novavax COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised



a. People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine or Pfizer COVID-19 Vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

- Novavax COVID-19 Vaccine remains authorized to provide:**
- A 2-dose primary series to people ages 12 years and older. The primary series doses are separated by 3–8 weeks. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine.
 - A booster dose in limited situations to people ages 18 years and older who previously completed primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine; have not received any previous booster dose(s); and are unable (i.e., contraindicated or vaccine not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series.